Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus LEXETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus LEXETTE.
CAPEX vs LEXETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid